Suspended CHO cell line for expressing hog cholera virus E2 protein and application of suspended CHO cell line in preparation of hog cholera vaccine

By using a CHO cell line that stably expresses classical swine fever virus E2 protein and a ferritin nanoparticle vaccine platform, the problems of insufficient DIVA properties and slow immune response speed of existing classical swine fever virus E2 protein vaccines have been solved, achieving rapid and effective immune protection.

CN119020260APending Publication Date: 2024-11-26HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411130700.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing classical swine fever virus E2 protein vaccines suffer from insufficient DIVA properties and slow immune response, making it difficult to provide effective protection in a short period of time.

Method used

A suspension CHO cell line stably expressing classical swine fever virus E2 protein was used to construct a ferritin nanoparticle vaccine platform using SpyCatcher/SpyTag technology. The E2 protein was presented on the surface of the ferritin nanoparticles to form Fe-E2 NPs, which were used for vaccine preparation and immunization.

Benefits of technology

Fe-E2 NPs can rapidly induce high-titer neutralizing antibodies and cellular immune responses in rabbits, providing early protection that is significantly superior to traditional C-strain vaccines. They also possess DIVA properties, enabling them to provide effective immunity against classical swine fever in a short period of time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020260A_ABST
    Figure CN119020260A_ABST
Patent Text Reader

Abstract

The invention discloses a suspended CHO cell line for expressing hog cholera virus E2 protein and application of the suspended CHO cell line in preparation of hog cholera vaccines. The invention provides a suspension CHO cell line for stably expressing hog cholera virus E2 protein, and the microbial preservation number of the suspension CHO cell line is CGMCC No.45825. The invention further provides a nanoparticle vaccine of the Fe-E2NPs, the nanoparticle vaccine of the Fe-E2NPs is obtained by coupling ST-E2 protein and ferritin, and the ferritin is obtained by fusing N-SpyCatcher protein to the N-terminal of the ferritin. The nanoparticle vaccine provided by the invention induces immune protection better than that of a C strain vaccine in a rabbit body, not only can induce IFN-gamma to provide early protection for swine fever, but also can induce effective humoral immunity more quickly, integrates the advantages of an attenuated live vaccine and a subunit vaccine, provides DIVA characteristics, and can be used for preparing a vaccine for treating swine fever. The vaccine can be an effective alternative vaccine for swine fever, and plays an important role in controlling and eradicating CSF.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a cell line stably expressing the E2 protein of classical swine fever virus and a classical swine fever nanoparticle vaccine, in particular to a suspended CHO cell line expressing the E2 protein of classical swine fever virus and a ferritin nanoparticle vaccine presenting the E2 protein on the surface prepared thereby, belonging to the field of classical swine fever vaccines. Background Art

[0002] Classical swine fever (CSF) is an acute, febrile, highly contagious disease of pigs caused by classical swine fever virus (CSFV). Its main clinical symptoms are fever, anorexia, ataxia and respiratory problems (Blome S, Staubach C, Henke J et al., Classical swinefever-an updated review. Viruses. 2017; 9(4): 86.). It is listed as one of the notifiable infectious diseases by the World Organization for Animal Health. After the implementation of vaccination and strict culling strategies, CSF has been successfully eradicated in many regions and countries. However, CSF is still prevalent in Asia, South America, Central America and the Caribbean. At present, CSF has changed from a typical acute and fatal infection to a chronic persistent infection (Coronado L, Bohórquez JA, S, et al., Investigation of chronic and persistent classical swine fever infections under field conditions and their impact on vaccine efficacy. BMC Vet Res. 2019; 15(1): 247.), which leads to new challenges in the eradication of classical swine fever through the culling strategy, so a subunit vaccine with equivalent immune effect to the C strain is needed to establish broad herd immunity. CSF reappeared in Japan 26 years after its disappearance, and CSFV samples were detected in both domestic pigs and wild boars, highlighting the complexity of today's CSF epidemic. The goal of the current CSFV strategy has shifted from simple prevention to eradication, which is a challenging task for the currently widely used C strain vaccine.

[0003] The widespread use of C-strain vaccines in China has effectively controlled CSF, resulting in no large-scale epidemics in recent years. However, C-strain vaccines cannot be DIVA by serological methods (Meyer D, Fritsche S, Luo Y et al., The double-antigen ELISA concept for early detection of Erns-specific classicalswine fever virus antibodies and application as an accompanying test for differentiation of infected from marker vaccinated animals. Transbound Emerg Dis. 2017; 64(6): 2013-2022.). In order to strengthen the prevention and control of CSF and better prepare for the eradication of CSF, the market demand for vaccines with DIVA characteristics is increasing.

[0004] Unlike live attenuated vaccines with the risk of virulence reversion, subunit vaccines are composed of immunogenic peptides, proteins or polysaccharides derived from pathogens. However, subunit vaccines generally exhibit low immunogenicity, so adjuvants are usually required to induce protective immune responses (Reed SG, Tomai M, Gale MJ Jr. New horizons in adjuvants for vaccine development. Curr Opin Immunol. 2020; 65: 97-101.). Even with adjuvants, subunit vaccines induce protective immune responses that are largely limited by the delivery method. Therefore, a suitable vaccine delivery platform is crucial for the development of subunit vaccines. The nanoparticle vaccine platform achieves the purpose of displaying and presenting antigens on nanoparticles in various ways, including chemical modification and gene fusion (Liu ZH, Xu HL, Han GW, et al. Self-Assembling Nanovaccine Enhances Protective Efficacy Against CSFV in Pigs. Front Immunol. 2021; 12: 689187.). Under the premise of non-fusion expression, nanoparticle vaccines are often developed as a general vaccine platform (Wang et al., 2019).

[0005] Nanoparticle vaccine platforms have been widely used in the development of various diseases, especially cancer vaccines, including preventive and therapeutic vaccines. One of the key advantages of nanoparticle-based vaccines is that they can induce effective and lasting immune responses. As a protein-based vaccine, nanoparticle vaccines are more capable of inducing humoral immunity than ordinary subunit vaccines. There are mainly the following factors. First, smaller NPs are more easily recognized and captured by APCs. In addition, NPs have the unique ability to enter lymph nodes directly, thereby providing continuous and powerful stimulation to germinal center B cells (GC B cells), inducing higher levels of somatic hypermutation, and rapidly producing B cells that secrete more specific neutralizing antibodies. In addition, previous reports have shown that after being captured by dendritic cells, NPs have a certain probability of cross-presentation, thereby presenting antigens through MHC-I and then inducing cellular immunity. In general, protein antigens are unstable and easily degraded in the complex humoral microenvironment of the body. This instability can lead to reduced delivery to antigen presenting cells (APCs) and ineffective immune responses. Nanoparticle-based delivery platforms provide a solution to this problem. At present, clinical trials of nanoparticle vaccines have begun, indicating that nanoparticle vaccines have great application prospects.

[0006] The E2 protein of classical swine fever virus is located on the surface of the viral envelope and plays a vital role in the process of viral infection. As a protective antigen, it can induce neutralizing antibodies (Gavrilov BK, Rogers K, Fernandez-Sainz IJ et al., Effects of glycosylation on antigenicity and immunogenicity of classical swine fever virus envelope proteins. Virology. 2011; 420 (2): 135-45), so new vaccines with E2 protein as the main component have been widely developed. It has been confirmed that subunit vaccines based on E2 protein have DIVA characteristics. However, vaccines based on E2 protein take a certain amount of time to induce protective immune responses and cannot provide protection as quickly as C strain vaccines. Given that C strain cannot distinguish between infected animals and vaccinated animals (DIVA), subunit vaccines induce protective immunity at a slower rate. Therefore, the market needs a classical swine fever vaccine that has both DIVA characteristics and can ensure rapid protection. Summary of the invention

[0007] One of the purposes of the present invention is to provide a suspension CHO cell line that stably expresses the E2 protein of classical swine fever virus;

[0008] The second object of the present invention is to provide a ferritin nanoparticle vaccine presenting E2 protein on the surface;

[0009] The third purpose of the present invention is to apply the suspended CHO cell line stably expressing the classical swine fever virus E2 protein or the ferritin nanoparticle vaccine presenting the E2 protein on the surface to the preparation of vaccines or drugs for preventing and treating classical swine fever.

[0010] The above-mentioned object of the present invention is mainly achieved through the following technical solutions:

[0011] One aspect of the present invention is to provide a suspension CHO cell line that stably expresses the E2 protein of classical swine fever virus, and its microbial preservation number is CGMCC No.45825; its classification name is: CHO suspension cell line that stably expresses the E2 protein of classical swine fever virus fused with Sp tag; the preservation time is: March 11, 2024; the preservation unit is: General Microbiology Center of China Microbiological Culture Collection Administration; the preservation address is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0012] Another aspect of the present invention is to use the suspension CHO cell line that stably expresses the classical swine fever virus E2 protein fused with the Sp tag to prepare a classical swine fever vaccine, including: inducing the suspension CHO cell line to express the ST-E2 protein; coupling or mixing the ST-E2 protein expressed by the suspension CHO cell line with a carrier or an immune adjuvant.

[0013] Another aspect of the present invention provides a ferritin nanoparticle vaccine presenting E2 protein on the surface, comprising: a ST-E2 protein expressed by a suspended CHO cell line that stably expresses the classical swine fever virus E2 protein and ferritin coupled thereto.

[0014] In a preferred embodiment of the present invention, the ferritin is a ΔN-SpyCatcher protein fused to the N-terminus of the ferritin, and the ΔN-SpyCatcher protein is displayed on the surface of the nanoparticle; wherein the amino acid sequence of the ΔN-SpyCatcher protein is shown in SEQ ID No.1, and the amino acid sequence of the ferritin is shown in SEQ ID No.2.

[0015] Another aspect of the present invention provides a method for preparing the ferritin nanoparticle vaccine presenting E2 protein on the surface, comprising:

[0016] The ST-E2 protein expressed by a suspension CHO cell line stably expressing the classical swine fever virus E2 protein and ferritin are incubated in a buffer at a molar ratio of (2-8):1 to obtain the product.

[0017] In a preferred embodiment of the present invention, ST-E2 protein expressed by a suspension CHO cell line stably expressing classical swine fever virus E2 protein and ferritin are incubated in a buffer at 4° C. at a molar ratio of 4:1.

[0018] Wherein, the buffer solution is preferably 50 mM PBS buffer solution with a pH value of 7.3.

[0019] The present invention selects ferritin from Helicobacter pylori to present antigen on the surface of nanoparticles, and uses the SpyCatcher / SpyTag coupling system for the combination of ferritin and E2 protein instead of direct fusion expression, thereby effectively avoiding the problem of low protein expression level.

[0020] The present invention firstly constructs a CHO suspension cell line that stably expresses CSFV E2 protein, and uses SpyCatcher / SpyTag technology to construct a universal subunit vaccine delivery platform with Ferritin as a carrier. Based on this, ferritin nanoparticles (Fe-E2NPs) presenting E2 protein on the surface are constructed, and their immunogenicity in rabbits is evaluated. The test results show that a single immunization with 20μg Fe-E2 NPs induces higher titers of neutralizing antibodies in rabbits. At each sampling time, the neutralizing antibody titer of the Fe-E2 NPs immunization group was significantly higher than that of the E2 protein immunization group. It is worth noting that at 7 and 14 days after immunization, Fe-E2 NPs induced high titer neutralizing antibodies earlier than the C strain vaccine. On the 7th day after immunization, the neutralizing antibody titer of the 20μg Fe-E2 NPs immunization group was significantly higher than that of the C strain immunization group (the average neutralization titer was 1:700) (P<0.01 and P<0.05). This demonstrates the early and strong immune response induced by Fe-E2 NPs. Importantly, at 7 days after immunization, the 20μg Fe-E2 NPs nanoparticle immunization group showed IFN-γ levels comparable to those of the C strain. This suggests that Fe-E2 NPs can exert an antiviral effect comparable to that of the C strain vaccine in the early stages of immunization. In addition, Fe-E2 NPs not only induce IFN-γ, but also rapidly induce high levels of neutralizing antibodies on the 7th day after immunization, with an average antibody titer of 1:700. Prior art studies have shown that neutralizing antibody titers ≥1:50 can effectively fight against virulent classical swine fever infection. Therefore, 20μg Fe-E2 NPs can quickly induce complete protective immunity against classical swine fever through humoral or cellular immune responses. In contrast, the C strain vaccine lacks the DIVA property, which is its main limitation for eliminating classical swine fever virus, while the Fe-E2-NP vaccine effectively makes up for this deficiency; the experimental results of the present invention show that the Fe-E2NPs nanoparticle vaccine provided by the present invention can induce better immune protection in rabbits than the C strain vaccine, and can not only induce IFN-γ to provide early protection against classical swine fever, but also can induce effective humoral immunity more quickly, taking into account the advantages of live attenuated vaccines and subunit vaccines, and may become an effective alternative vaccine for classical swine fever, providing DIVA properties, and is expected to play an important role in controlling and eradicating CSF. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Molecular design of Fe-E2 nanoparticles (Fe-E2 NPs).

[0022] Figure 2 To construct and identify the suspension CHO-ST-E2 cell line.

[0023] Figure 3 Structural characteristics of Fe-E2 nanoparticle vaccine (Fe-E2 NPs).

[0024] Figure 4 is the humoral immunity level induced by Fe-E2 nanoparticle vaccine (Fe-E2 NPs).

[0025] Figure 5 Cellular immunity induced by Fe-E2 nanoparticle vaccine (Fe-E2 NPs).

[0026] Figure 6 The figure shows the changes in body temperature of individual rabbits in each group after infection with strain C. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0028] Experimental Example 1 Construction and identification of a CHO suspension cell line stably expressing CSFV E2 protein, construction, identification and immunoprotective performance determination of ferritin nanoparticle vaccine (Fe-E2 NPs) presenting E2 protein on the surface

[0029] 1 Materials and test methods

[0030] 1.1 Plasmids, cells and viruses

[0031] Plasmids pCold-I, pLVX-IRES-Zsgreen, pSPAX2 and pMD2.G were stored in the laboratory of the inventor. Expi-CHO-S cell line was also stored in the laboratory of the inventor and cultured in a medium supplemented with L-glutamine. HEK293T cells were cultured in DMEM medium (Cat. No. C11995500BT) supplemented with 10% fetal bovine serum (FBS) (Cat. No. A5669701; Gibco). CSFV-SM and C strain were both stored in the inventor's laboratory.

[0032] 1.2 Design and cloning of SC ferritin and ST-E2

[0033] The △N-SpyCatcher-Ferritin gene sequence, which is a fusion of △N-SpyCatcher (GeneBank: MH425515) and Ferritin (UniProt: Q9ZLI1), was codon-optimized in E. coli, synthesized by a biotechnology company, and then cloned into pCold-I with an amino-terminal hexahistidine tag. The △N-SpyCatcher protein was fused to the N-terminus of ferritin to ensure that the △N-SpyCatcher protein was displayed on the surface of the nanoparticles ( Figure 1 A and Figure 1 B).

[0034] The amino acid sequence of △N-SpyCatcher is shown in SEQ ID No. 1: MGSSAMVDTLSGLSSEQGQSGDMTIEEDSATHIKFSKRDEDGKELAGA TMELRDSSGKTISTWISDGQVKDFYLYPGKYTFVETAAPDGYEVATAIT FTVNEQGQVTVNGKATKGDAHIS (SEQ ID No. 1)

[0035] The amino acid sequence of the ferritin protein is shown in SEQ ID No. 2: MLSKDIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIVFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYGHEQHISESINNIVDHAIKNKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS* (SEQ ID No. 2)

[0036] The pCold-I expression plasmid containing the N-SpyCatcher-Ferritin fusion gene sequence was transformed into BL21 (DE3) competent cells (TIANGEN). After culturing overnight at 37°C on LB agar plates supplemented with 50 μg / mL ampicillin, a single positive colony was picked into 10 mL liquid LB medium containing 50 μg / mL ampicillin. The culture was cultured overnight at 37°C, 220 rpm.

[0037] SpyTag-E2 (GeneBank: ANI21172.1) with a transmembrane region deleted for the preparation of Ferritin-E2 NP vaccine was optimized and synthesized by a biological company for Chinese hamster codons. It was then cloned into the pLVX-IRES-Zsgreen plasmid, which has an N-terminal Kozak sequence, a GT6 signal peptide for protein secretion expression, a 13-residue SpyTag for coupling with SpyCatcher, and a C-terminal 6×His-Tag. The resulting plasmid was named pLVX-ST-E2. The pLVX-ST-E2 plasmid was then extracted from E. coli DH5 using the EndoFree Maxi plasmid kit (DP117; TIANGEN) according to the manufacturer's protocol.

[0038] 1.3SC ferritin expression and purification

[0039] The activated pCold Fe BL21 (DE3) bacteria were added to a 3L conical shake flask containing 1L of liquid LB medium containing 50μg / mL ampicillin and cultured at 37°C with shaking at 220rpm. When the OD600nm value of the culture reached the range of 0.6-0.8, isopropylthiogalactoside (IPTG) was added to the conical flask at a final concentration of 1mM to induce protein expression. The induction conditions were 16°C, 110rpm, and the induction time was 16-20h. After induction, the bacterial culture was harvested by centrifugation at 4°C, 8000×g for 3 minutes. The resulting precipitate was resuspended in 50mM PBS at pH 7.3 and then lysed by ultrasound. The lysate was centrifuged at 4°C, 12000×g for 20min, and the supernatant was filtered using a Striptop filter cartridge with a pore size of 0.45μm. The concentrated supernatant was then purified by affinity chromatography using Ni Sepharose High Performance (Cytiva) in a WET FRED gravity flow column (Byotime). The target protein was eluted with a buffer containing 50 mM PBS (pH 7.3), 300 mM imidazole, and stored at 4°C until use.

[0040] 1.4 Construction and identification of CHO-ST-E2 suspension cell line

[0041] ST-E2 protein was produced in Expi-CHO-S cells. During the transfection process, 10.5 μg of pLVX-ST-E2, 7 μg of pSPAX2, and 3.5 μg of pMD 2.g plasmids were co-transfected into HEK293T cells using X-trem GENE HP DNA (Sigma-aldrich). After 24 h, the green fluorescence signal was observed under a fluorescence microscope to determine the transfection effect. After 48 h, the lentivirus was collected and concentrated using an Amicon Ultra-15 centrifugal filter device (Millipore, UFC901096), and then 30 mL of Expi-CHO-S cells were infected with the lentivirus. After 48 h after transduction, the green fluorescence signal in the cells was observed under a fluorescence microscope to determine whether the transduction was successful, and the CHO-ST-E2 suspension cell line was obtained. 72 h after transduction, the secretory expression of recombinant ST-E2 in the transduced cells was detected by western blotting analysis. During the verification process, 1 ml of cell culture medium was taken, centrifuged at 12000rpm for 10 minutes, the supernatant was taken, and combined with 30 microliters of Ni Sepharose High Performance resin at 4°C overnight, then centrifuged at 500×g for 10 minutes, the supernatant was aspirated, the precipitate was resuspended with 160 microliters of PBS, and then 40 microliters of 5× Loading buffer were added, and the sample was boiled in boiling water for 15 minutes. The non-transduced cells were treated in the same way as the control group. Then western blotting was performed for identification, and the steps were as follows: first, the protein sample was subjected to 12.5% ​​sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the protein bands were electrotransferred to a nitrocellulose membrane using a semi-dry transfer device (Bio-Rad), and then the membrane was placed in a blocking buffer (PBS containing 5% skim milk) at room temperature for 2 hours, washed three times with PBS-Tween 20 (PBST), 5 minutes each time, and then placed in a specific His tag antibody (1:1000) or CSFV E2 monoclonal antibody (WH303) (1:1000) at room temperature for 2 hours, washed three times with PBS-Tween 20 (PBST), 5 minutes each time, and then placed in IRDye 800CW secondary antibody (1:10000) at room temperature for 1 hour in the dark. Finally, the membrane was scanned and analyzed using the Odyssey near-infrared laser scanning imaging system (Li-Cor Bioscience).

[0042] The cells were continuously cultured in suspension for 8 days. 1 ml of supernatant was taken every day, centrifuged at 12000rpm for 10 minutes, 160 μl of supernatant was taken, and then 40 μl of 5× Loading buffer was added to cook the sample for later use. The western blotting steps in the expression verification were used to detect the relationship between the expression level and the culture time and further determine the optimal period for protein purification. The CHO-ST-E2 suspension cell line was continuously subcultured for at least 20 generations, and then the stable expression of the recombinant protein was verified by western blotting.

[0043] 1.5 Expression and purification of ST-E2 protein

[0044] After 3 days, the infected cells were centrifuged at 500×g for 5 min at room temperature, and the cell culture volume was increased to 60 mL. After 3 days, half of the cells were stored in liquid nitrogen, while the remaining cells were further cultured in another 300 mL of culture medium. After 5 days of culture, the cells were precipitated by centrifugation at 8000×g for 10 min at 4°C, and the resulting supernatant was filtered using a Striptop filter cartridge with a pore size of 0.45 μm. Subsequently, the supernatant was purified by affinity chromatography using Ni Sepharose HighPerformance (Cytiva) in a WET FRED gravity flow column (Byotime). The target protein was eluted with a buffer containing 50 mM PBS (pH 7.3), 300 mM imidazole, and stored at 4°C for future use.

[0045] 1.6 Preparation and purification of ferritin-E2 nanoparticles (Fe-E2 NPs)

[0046] To assemble E2-conjugated nanoparticles, ST-E2 was incubated with ΔN-SpyCatcher Ferritin to form a stable covalent peptide bond. Purified ΔN-SpyCatcher Ferritin (SC-Fe) at a concentration of 50 μM was incubated with excess SpyTag-E2 (ST-E2) at a 1:4 molar ratio in 50 mM PBS at 4°C, pH 7.3 overnight. To separate the conjugated nanoparticles from empty NPs and ST-E2, all preparations were purified by size exclusion chromatography (SEC) on a Superose 6Increase10 / 300GL gel filtration column pre-equilibrated with 50 mM HEPES, pH 7.3, 300 mM NaCl. Fractions were collected for Western blot analysis. The target protein (Fe-E2 NPs) was selected, concentrated, and stored at 4°C. The assembly of nanoparticles was observed by transmission electron microscopy (TEM) in a negative staining state.

[0047] 1.7 Animal immunization and challenge

[0048] Twenty-four healthy New Zealand white rabbits, each weighing approximately 2 kg, were used in the experiment. These rabbits were purchased from Harbin Veterinary Research Institute. Prior to the experiment, all rabbits were tested for CSFV E2 antibodies using a blocking ELISA assay to confirm that the rabbits were all CSFV negative. The rabbits were divided into six groups of four rabbits each. Four groups of rabbits were immunized with: 10 μg ST-E2 protein, 10 μg Fe-E2 NPs, 20 μg ST-E2 protein, and 20 μg Fe-E2 NPs, all mixed with MONTANIDE ISA 15A VG adjuvant (SEPPIC, France) at a volume ratio of 85:15. Another group was immunized with 100 MID C strain, and the last group was immunized with 2 mL PBS as a control group. All groups were injected with 1 mL each in the muscles of both hind legs of the rabbits. 15 days after vaccination, all rabbits were challenged with 100 MID of CSFV C strain. Before the challenge, the rectal temperature of all rabbits was measured. Starting from 24 h after the challenge, the rectal temperature of the rabbits was measured every 6 h for 90 h as the basis for judging the typical fever of the rabbits.

[0049] 1.8ELISA

[0050] According to the manufacturer's instructions (CSFV antibody detection kit, IDEXX, USA), the serum was tested for the presence of CSFV-specific antibodies by blocking ELISA. All serum samples collected at 0, 7, 14 and 19 days after immunization were subjected to ELISA. In this assay, any antibodies present in the test sample will block the binding of the horseradish peroxidase-coupled swine fever-specific monoclonal antibody to the swine fever antigen, thereby enabling the detection and quantification of swine fever-specific antibodies in the serum sample. 4 days after the challenge, the IFN-γ level in the serum sample was measured by double antibody sandwich ELISA (MEIMIAN).

[0051] 1.9 Serum virus neutralization test

[0052] To evaluate the neutralizing antibody levels of serum samples, the serum was inactivated in a 56°C water bath for 30 min. The serum was then serially diluted two-fold to a final dilution of 12,800. Then, 100 μL of CSFV-SM (containing 200 TCID 50 / mL) was mixed with 100 μL of serum of different dilutions to form a 1:1 mixture of serum and CSFV-SM. The mixture was incubated at 37°C for 1 hour. Next, the virus-serum mixture was added to PK-15 cells pre-seeded in a 96-well plate. After adsorption for 1 hour, the mixture was discarded, and DMEM cell culture medium containing 2% FBS was added and cultured for 2 days at 37°C and 5% CO2. In order to observe the situation of CSFV-infected cells in each well, immunofluorescence assay (IFA) was performed. The titer of neutralizing antibodies was calculated and expressed as the Log2 value of the highest dilution that inhibited PK-15 cell infection in 50% of the culture wells.

[0053] 1.10 Lymphocyte proliferation assay

[0054] To determine whether Fe-E2-NPs activated T lymphocytes, lymphocytes were isolated from rabbit spleen using a rabbit spleen lymphocyte isolation kit (Solarbio). The isolated cells were then adjusted to 1 × 10 7 Cells / mL. Subsequently, the prepared lymphocyte suspension was added to a 96-well plate at 100 μL / well. In order to stimulate the cells, 100 μL of 10 μg / mL ST-E2 protein solution was added to each well, and the 96-well plate was incubated at 37°C for 72 h. After the incubation period, 40 μL of MTS reagent was added to each well, and the plate was further incubated at 37°C for 4 h. The absorbance value at 450 nm was then measured, and the stimulation index was calculated using the formula stimulation index (SI) = OD value of the immune group / OD value of the blank control group.

[0055] 1.11 IFN-γ Elispot

[0056] Peripheral blood mononuclear cells (PBMCs) (Solarbio) were isolated from peripheral blood treated with heparin and adjusted to 4 × 10 6 100 μL of anti-rabbit IFN-γ antibody was added to each well of a PVDF membrane multiwell plate (Millipore), incubated overnight at 4°C, and then washed with PBS. Next, 200 μL of 10% FBS RPMI-1640 medium was added to each well and incubated at room temperature for 30 min. The medium was discarded and 50 μL of the prepared PBMC suspension was added to each well. Subsequently, 50 μL of 100 μg / mL E2 protein solution was added to ensure that there were 1×10 cells / mL in each well. 6cells and 5 μg E2 protein. The plates were wrapped in aluminum foil and incubated at 37°C, 5% CO2 for 48 h, then washed with PBS. Then, 100 μL of 0.1 μg / mL biotinylated anti-rabbit IFN-γ (MT318) was added to each well and incubated for 2 h at room temperature, then washed again with PBS. Subsequently, 100 μL of streptavidin HPR (diluted 1:1000) was added to each well, incubated for 1 h at room temperature, and washed with PBS. To observe the spots, 100 μL of TMB substrate was added to each well. When the spots appeared, the plates were rinsed with deionized water until the spots no longer spread. The plates were then dried and the spots were counted using the ISpot SpectrumELR088IFL.

[0057] 1.12 Quantitative PCR

[0058] Total RNA was extracted from spleen grinds using a kit (EX18230301; GM Biotech). Subsequently, cDNA was synthesized using avian myeloblastosis virus reverse transcriptase XL (TIANGEN) in a volume of 20 μL. The copy number of the CSFV genome was quantified using RT-qPCR as previously described (Zhao et al., 2008).

[0059] 1.13 Data Analysis

[0060] The data were analyzed using independent sample t-test in Graphpad 8.0.2, and statistical significance was determined as *P < 0.05, **P < 0.01, ***P < 0.001.

[0061] 2 Test results

[0062] 2.1 Identification of CHO-ST-E2 suspension cell line

[0063] 24h after transfection, a large number of fluorescent signals were observed in the cells under an inverted fluorescence microscope, indicating that the packaging plasmid was successfully transferred into 293T cells ( Figure 2 A). 48 hours after the collected lentivirus was transduced into Expi-CHO-S cells, the suspended cells were observed to emit green fluorescence under a fluorescence microscope, indicating that the lentivirus successfully infected the Expi-CHO-S cells and integrated the corresponding gene fragments into the cell line genes ( Figure 2 A). Western blotting results showed that the CHO-ST-E2 suspension cell line successfully secreted and expressed ST-E2 protein, indicating that the ST-E2 secretory expression sequence was successfully integrated into the cell line gene. The western blotting results of the expression samples for 8 consecutive days showed that the protein expression level showed a continuous increasing trend ( Figure 2B), but in the process of cell culture, it was found that on the 6th day of expanded culture, the cells began to die, and on the 7th day, all the cells died. Therefore, on the 5th day, a large amount of protein can be obtained, and the cells can be subcultured to continue to express the protein. Considering the subsequent industrial sustainable application, the sampling time is selected as the 5th day after expanded culture. After 20 generations of continuous subculture, the supernatant of each generation was detected by western blotting to secrete and express ST-E2 protein, proving that the CHO-ST-E2 suspension cell line can continuously and stably express ST-E2 protein ( Figure 2 B).

[0064] 2.2 Structural characterization of ferritin-E2 nanoparticles

[0065] ST-E2 protein and SC-Fe were purified separately. They were coupled overnight at a molar ratio of SC-Fe:ST-E2 of 1:4, and then Ferritin-E2 NPs (Fe-E2 NPs) were further purified using size exclusion chromatography (SEC). The results showed that the size of Ferritin-E2 NPs was significantly larger than that of Ferritin alone, as evidenced by the shift of the SEC elution peak from 13.5 mL to 9.5 mL ( Figure 3 A). In addition, the binding of SC-Fe and ST-E2 was verified by Western blotting ( Figure 3 B).

[0066] like Figure 3 As shown in Figure C, the structural features of the E2-coupled nanoparticles were observed using negative staining electron microscopy (EM). The image showed that Ferritin-E2 was successfully assembled into nanoparticles, confirming the formation of E2-coupled nanoparticles ( Figure 3 C).

[0067] 2.3NPs induce swine fever-specific antibody response in rabbits

[0068] To evaluate the ability of Fe-E2 nanoparticle vaccine (Fe-E2 NPs) to induce protective immune responses, six groups of rabbits ( Figure 4 A).

[0069] All serum samples collected from rabbits were tested for blocking CSFV-specific antibodies using a blocking ELISA. Notably, no CSFV antibodies were detected in serum samples on day 0, indicating that all rabbits were initially CSFV-negative individuals ( Figure 4 B).

[0070] The results showed that on the 7th day after immunization, the blocking rate in the serum of rabbits immunized with Fe-E2 NPs was significantly higher than that of rabbits immunized with ST-E2, with an average value of 75.20% and 79.25%, respectively. In addition, the neutralizing antibody titer in the serum samples of rabbits immunized with Fe-E2 NPs was significantly higher, with an average value of 1:503 and 1:700, respectively, while the average values ​​of rabbits immunized with ST-E2 were 1:6 and 1:40.5, respectively.

[0071] Although there was no significant difference in antibody blocking rate between the two doses of Fe-E2 NPs immunization group and the ST-E2 immunization group on day 14 after immunization, the neutralizing antibody titer of the Fe-E2 NPs immunization group (mean values ​​of 1:618 and 1:2600, respectively) was significantly higher than that of the ST-E2 immunization group (mean values ​​of 1:6 and 1:109, respectively) ( Figure 4 C and D). In addition, at 4 days post-challenge (dpc), at a 20 μg immunization dose, significant differences (P < 0.01 and P < 0.001, respectively) in CSFV antibody blocking rates (mean values ​​were 85.55% and 91.90%, respectively) and neutralizing antibodies (mean values ​​were 1:142.5 and 1:10000, respectively) were observed between the ST-E2 and Fe-E2 NPs-vaccinated groups.

[0072] This study focused on the differences in swine fever-specific antibodies induced by Fe-E2 NPs and C strain immunization groups, and found that Fe-E2 NPs could continuously induce CSFV-specific antibodies. At 7 and 14 days after immunization, the antibody blocking rate showed an upward trend and remained at a high level (the average value increased from 79.25% to 85.26%). In contrast, the antibody level in the C strain immunization group showed a downward trend (the average value decreased from 73.65% to 68.21%), which was significantly lower than that in the Fe-E2 NPs immunization group (P<0.01). It is worth noting that even on the 4th day after the attack, the antibody blocking rate in the Fe-E2 NPs immunization group was still significantly higher than that in the C strain immunization group (the average values ​​were 91.90% and 90.83, respectively) (P<0.05).

[0073] On the 7th day after the first immunization, the neutralizing antibody level in the 20μg Fe-E2 NPs immunization group (mean value, 1:700) was higher than that in the C strain immunization group (mean value, 1:262.5) (P<0.01), and 2 of the 4 rabbits in the 10μg Fe-E2 NPs immunization group produced high levels of neutralizing antibodies (mean values, 1:800 and 1:1200, respectively). On the 14th day after the first immunization, the neutralizing antibody titers increased in both the C strain group (mean value increased from 1:262.5 to 1:1000) and the 20μg Fe-E2 NPs group (mean value increased from 1:700 to 1:2600). However, the neutralizing antibody level in the C strain immunization group was still significantly lower than that in the 20μg Fe-E2 NPs group (P<0.05). On day 4 after challenge, the neutralizing antibody titers increased in all groups, with no significant difference between the C strain group and the 20 μg Fe-E2 NPs group (mean values ​​were 1:10,400 and 1:10,000, respectively) ( Figure 4 C and D).

[0074] 2.4Fe-E2 NPs induce strong cellular immune response in rabbits

[0075] IFN-γ induced by C strain immunization plays a vital role in preventing classical swine fever infection in the early stage of immunization. Seven days after immunization, C strain can induce a certain level of IFN-γ to resist classical swine fever infection. Therefore, this experiment focused on the IFN-γ level in serum samples collected 7 days after immunization. Figure 5 As shown in A, high levels of IFN-γ were detected in serum samples of both the C strain group (about 145.7ρg / mL) and the 20μg Fe-E2NPs group (about 140.8μg / mL). In contrast, the ST-E2 group hardly induced IFN-γ, and the serum content was comparable to that of the PBS control group (about 120ρg / mL). These results indicate that Fe-E2 NPs successfully induced CSFV-specific cellular immunity comparable to that of the C strain, while subunit vaccines based on the E2 protein failed to induce cellular immunity.

[0076] To further determine the differences between ST-E2 and Fe-E2 NPs protein subunit vaccines in inducing cellular immunity, the number of IFN-γ-secreting cells in the four protein subunit vaccine groups was measured using ELIspot. Figure 5 As shown in B, at the same dose, the 10 μg and 20 μg Fe-E2 NPs groups had 10 6The number of spots of cells in the Fe-E2 NPs group (mean values ​​were 173 and 741, respectively) was significantly higher than that in the ST-E2 group (mean values ​​were 65 and 86, respectively) (P<0.05 and P<0.0001). Similarly, the results of lymphocyte proliferation showed that at the same dose, the stimulation index (SI) of the Fe-E2 NPs group (mean values ​​were 1.31 and 1.65, respectively) was significantly higher than that of the ST-E2 group (mean values ​​were 1.04, respectively) (P<0.05), and the number of IFN-γ secreting cells and SI in the 20μg Fe-E2 NPs group were significantly higher than those in the 10μg Fe-E2 NPs group ( Figure 5 C), indicating that a certain dose of nanoparticles is required to stimulate the body to produce cellular immunity.

[0077] 2.5 Ferritin NPs induce complete protection of rabbits against classical swine fever virus

[0078] Fifteen days after the first immunization, all rabbits were challenged with 100 MID of strain C virus. The temperature responses of the rabbits were as follows: Figure 6 As shown. It is noteworthy that rabbits immunized with strain C and 20 μg Fe-E2 NPs did not show fever after challenge. Half of the rabbits in the 20 μg ST-E2 and 10 μg Fe-E2 NPs groups developed fever, while all individuals in the 10 μg ST-E2 and PBS control groups developed fever ( Figure 6 and Table 1).

[0079] At 90 h after challenge, spleens were collected from rabbits and the viral genome was detected using quantitative RT-PCR. Approximately 10% of the febrile rabbits in the PBS group were detected. 4 In the ST-E2 immunization group and the 10 μg Fe-E2 NPs immunization group, about 10 2 In addition, about 10 μg ST-E2 was detected in one febrile rabbit sample. 3 In contrast, no viral nucleic acid was detected in the spleens of rabbits immunized with 20 μg Fe-E2 NPs and strain C (Table 1).

[0080] Table 1 Virus load and fever in rabbit spleen after infection with C strain

[0081]

[0082] -: Not detecable

Claims

1. A suspension CHO cell line stably expressing the Classical Swine Fever Virus E2 protein, characterized in that: Its microbial preservation number is CGMCC No.45825.

2. A swine fever nanoparticle vaccine, characterized in that: include: ST-E2 protein and ferritin expressed by the suspension CHO cell line stably expressing classical swine fever virus E2 protein as described in claim 1.

3. The swine fever nanoparticle vaccine according to claim 2, characterized in that: The ST-E2 protein expressed by the suspension CHO cell line stably expressing the classical swine fever virus E2 protein as claimed in claim 1 is coupled with ferritin.

4. The swine fever nanoparticle vaccine according to claim 2, characterized in that: The ferritin is prepared by fusing the ΔN-SpyCatcher protein to the N-terminus of the ferritin, and displaying the ΔN-SpyCatcher protein on the surface of the nanoparticle.

5. The swine fever nanoparticle vaccine according to claim 4, characterized in that: The amino acid sequence of the ΔN-SpyCatcher protein is shown in SEQ ID No.1, and the amino acid sequence of the ferritin is shown in SEQ ID No.

2.

6. A method for preparing the swine fever nanoparticle vaccine according to any one of claims 2 to 5, characterized in that: include: The ST-E2 protein expressed by the suspension CHO cell line stably expressing the classical swine fever virus E2 protein according to claim 1 and ferritin are incubated in a buffer at a molar ratio of (2-8):1 to obtain the product.

7. The method according to claim 6, characterized in that The ST-E2 protein expressed by the suspension CHO cell line stably expressing the classical swine fever virus E2 protein and ferritin were incubated in a buffer at 4° C. according to a molar ratio of 4:1 to obtain the product.

8. The method according to claim 6, characterized in that The buffer solution is 50 mM PBS buffer solution with a pH value of 7.

3.

9. Use of the suspension CHO cell line stably expressing the Classical Swine Fever Virus E2 protein according to claim 1 in the preparation of Classical Swine Fever vaccine.

10. A vaccine composition for preventing and treating swine fever, characterized in that: Contains the swine fever nanoparticle vaccine according to any one of claims 2-5.